ARTICLE | Clinical News
LymphoCide epratuzumab: Phase III trial update
October 2, 2000 7:00 AM UTC
Immunomedics Inc. (IMMU), Morris Plains, N.J. Product: LymphoCide epratuzumab Business: Cancer Therapeutic category: Immune stimulation Target: CD22 Description: Humanized anti-CD22 monoclonal anti...